Femara First-Line Breast Cancer Label Includes Tamoxifen Superiority Claim
Executive Summary
Novartis' Femara (letrozole) first-line breast cancer approval Jan. 10 is based on superiority over tamoxifen (AstraZeneca's Nolvadex and Barr's generic).
You may also be interested in...
Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome
Nolvadex Pediatric Exclusivity Extension Would Block Generics Until 2003
AstraZeneca expects to receive a pediatric exclusivity extension for the breast cancer agentNolvadex (tamoxifen) based on studies in McCune-Albright syndrome
ODE V Deputy Bull Will Step In "As Needed" For Novartis-Bound DeLap
FDA Office of Drug Evaluation V Deputy Director Jonca Bull, MD, is serving as the office's acting director in areas where departing Director Robert DeLap, MD/PhD, has conflicts of interest.